Cardiome Selects Quintiles To Manage Global Regulatory Affairs And Life Cycle Safety Activities For BRINAVESS Vernakalant IntravenousCardiome Pharma Corp.NewsRx.com
By a News Reporter-Staff News Editor at Marketing Weekly News -- Cardiome Pharma Corp. (NASDAQ: CRME /
TSX: COM) announced the selection of Quintiles to provide comprehensive post-marketing lifecycle safety and global regulatory affairs services for BRINAVESS. Quintiles, the world's leading provider of biopharmaceutical services, will begin providing these services effective immediately as Cardiome continues to prepare for the anticipated transfer of BRINAVESS from Merck to Cardiome.
"We are very pleased to begin our partnership with Quintiles during the pending return of global rights for the intravenous (IV) and oral formulations of vernakalant to Cardiome," stated William Hunter, M.D., interim CEO of Cardiome. "Finding a highly capable service provider to deliver operational regulatory and pharmacovigilance support was a key priority to effectively and expeditiously transfer the registered marketing authorizations from Merck to Cardiome. We believe that Quintiles' global reach and extensive expertise in these areas will help facilitate a seamless worldwide transition."
In September 2012, Merck informed Cardiome that Merck (through two of its subsidiaries) would return the global marketing and development rights for both the intravenous and oral formulations of vernakalant to Cardiome. Vernakalant IV is marketed under the brand name BRINAVESS. BRINAVESS has received approval in the European Union and certain other markets worldwide for the rapid conversion of recent onset atrial fibrillation
(AF) to sinus rhythm in adults: for non-surgery patients with AF of seven days or less and for post-cardiac surgery patients with AF of three days or less. Vernakalant IV is not approved for use in the United States or Canada.
About Cardiome Pharma Corp. Cardiome Pharma Corp. is a biopharmaceutical company dedicated to the discovery, development and commercialization of new therapies that will improve the health of patients around the world. Cardiome has one marketed product, BRINAVESS (vernakalant IV), approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults.
Cardiome is traded on the NASDAQ Capital Market (CRME) and the Toronto Stock Exchange (COM). For more information, please visit our web site at www.cardiome.com.
Keywords for this news article include: Drugs, Therapy, Marketing, Advertising, Biopharmaceuticals, Atrial Fibrillation, Cardiome Pharma Corp..
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC